2023 World Conference on Lung Cancer (Posters)-P1.25. Stereotactic Ablative Body Radiotherapy for Early NSCLC: Changes in Pulmonary Function, Dyspnoea and Quality of Life

P1.25. Stereotactic Ablative Body Radiotherapy for Early NSCLC: Changes in Pulmonary Function, Dyspnoea and Quality of Life - PDF(Slides)

Back to course

Pdf Summary

Stereotactic ablative body radiotherapy (SABR) is a non-invasive treatment option for patients with early-stage non-small cell lung cancer (NSCLC) who are not suitable for surgery. This study aimed to evaluate the changes in pulmonary function, dyspnea, and quality of life in NSCLC patients treated with SABR.<br /><br />The study included a large cohort of 119 NSCLC patients who underwent SABR treatment between July 2013 and July 2019. The patients were evaluated for objective pulmonary function, clinician-reported and patient-reported outcomes. The results showed a minor decline in pulmonary function with statistically significant decline in forced expiratory volume in 1 second (FEV1) at 18 months post SABR. Smoking pack years was found to be a predictor for declining pulmonary function. Patient-reported dyspnea scores worsened at the 18-month time point, while global quality of life scores did not show significant changes. Clinician-reported outcomes did not show significant changes either.<br /><br />The findings of this study are consistent with previous research that has shown a decline in pulmonary function following SABR treatment for NSCLC. However, it is important to note that most of the patients in this study had underlying lung conditions and poor baseline pulmonary function. The decline in pulmonary function may be attributed to the natural progression of their disease. The quality of life impact of this decline in pulmonary function was not severe.<br /><br />Overall, this study provides valuable insights into the effects of SABR on pulmonary function, dyspnea, and quality of life in NSCLC patients. It highlights the need for careful consideration of patient characteristics and smoking history when assessing the potential impact of SABR on pulmonary function. Further research is needed to better understand the long-term effects of SABR on these outcomes.

Asset Subtitle

Julie Ahn

Meta Tag

Speaker Julie Ahn

Topic Early-Stage NSCLC: Changing Paradigms & Outcomes

Keywords

Stereotactic ablative body radiotherapy

SABR

non-small cell lung cancer

NSCLC

pulmonary function

dyspnea

quality of life

forced expiratory volume in 1 second

FEV1

smoking pack years